• 1
    Kurman RJ,Henson DE,Herbst AL,Noller KL,Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA. 1994; 271: 18661869.
  • 2
    Walsh JM. Cervical cancer: developments in screening and evaluation of the abnormal Pap smear. West J Med. 1998; 169: 304310.
  • 3
    Hewitt M,Devesa SS,Breen N. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. Prev Med. 2004; 39: 270278.
  • 4
    Swan J,Breen N,Coates RJ,Rimer BK,Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 15281540.
  • 5
    National Center for Health Statistics. National Health Interview Survey, 2000. Adult sample. Hyattsville, Md: U.S. Department Of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2001.
  • 6
    National Center for Health Statistics. National Health Interview Survey, 2005. Sample adult cancer file. Hyattsville, Md: U.S. Department Of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2006.
  • 7
    Botman SL,Moore TF,Moriarity CL,Parsons VL. Design and estimation for the National Health Interview Survey, 1995-2004. National Center for Health Statistics. Vital Health Stat.2(130) 2000.
  • 8
    Kulasingam SL,Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781789.
  • 9
    Sirovich BE,Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med. 2004; 19: 243250.
  • 10
    Siller AB,Tompkins L. The big four: analyzing complex sample survey data using SAS, SPSS, STATA, and SUDAAN. In: Proceedings of the Thirty-first Annual SAS Users Group International Conference 2006. SII ed. Cary, NC: SAS Institute; 2006.
  • 11
    U.S. Census Bureau. Annual projections by single year of age by sex. U.S. Census Bureau; 2005. Available from URL:
  • 12
    U.S. Food and Drug Administration. New Device Approval. Digene Hybrid Capture 2 High-Risk HPV DNA test-P890064 S009 A004. Rockville, Md: U.S. Food and Drug Administration, Center for Devices and Radiological Health; 2003.
  • 13
    American College of Obstetricians and Gynecologists. ACOG practice bulletin. Cervical Cytology screening. Number 45, August 2003. Int J Gynaecol Obstet. 2003; 83: 237247.
  • 14
    Saslow D,Runowicz CD,Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342362.
  • 15
    Clavel C,Cucherousset J,Lorenzato M, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer. 2004; 90: 18031808.
  • 16
    Cuzick J,Szarewski A,Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003; 362: 18711876.
  • 17
    Sherman ME,Lorincz AT,Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95: 4652.
  • 18
    Hiatt RA,Klabunde C,Breen N,Swan J,Ballard-Barbash R. Cancer screening practices from National Health Interview Surveys: past, present, and future. J Natl Cancer Inst. 2002; 94: 18371846.
  • 19
    Insinga RP,Glass AG,Rush BB. Pap screening in a U.S. health plan. Cancer Epidemiol Biomarkers Prev. 2004; 13: 355360.
  • 20
    Franco EL,Cuzick J,Hildesheim A,de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006; 24( suppl 3): S171S177.
  • 21
    Irwin K,Montano D,Kasprzyk D, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol. 2006; 108: 397409.
  • 22
    Mayrand MH,Duarte-Franco E,Coutlee F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer. 2006; 119: 615623.
  • 23
    Twombly R. U.S. girls to receive HPV vaccine but picture unclear on potential worldwide use, acceptance. J Natl Cancer Inst. 2006; 98: 10301032.
  • 24
    Newell SA,Girgis A,Sanson-Fisher RW,Savolainen NJ. The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am J Prev Med. 1999; 17: 211229.
  • 25
    McGovern PG,Lurie N,Margolis KL,Slater JS. Accuracy of self-report of mammography and Pap smear in a low-income urban population. Am J Prev Med. 1998; 14: 201208.
  • 26
    Caplan LS,McQueen DV,Qualters JR,Leff M,Garrett C,Calonge N. Validity of women's self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiol Biomarkers Prev. 2003; 12(11 pt 1): 11821187.
  • 27
    Wiseman C. National Cytology Proficiency Testing Update. Addendum F. In: Clinical Laboratory Improvement Advisory Committee. U.S. Department of Health and Human Services. Atlanta, Georgia, February 8-9, 2006. Available at:
  • 28
    Jones BA,Valenstein PN,Steindel SJ. Gynecologic cytology turnaround time. A College of American Pathologists Q-Probes Study of 371 laboratories. Arch Pathol Lab Med. 1999; 123: 682686.
  • 29
    Saraiya M,Lee NC,Blackman D,Smith MJ,Morrow B,McKenna MT. Observations from the CDC. An assessment of Pap smears and hysterectomies among women in the United States. J Womens Health Gend Based Med. 2002; 11: 103109.
  • 30
    Boyle JP,Honeycutt AA,Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001; 24: 19361940.
  • 31
    Hootman JM,Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006; 54: 226229.